Shares of Hims & Hers are trading marginally lower Monday morning, as competitive news overshadows bullish announcements from ...

Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...

Hims & Hers Health (NYSE:HIMS) said it is holding discussions with Novo Nordisk (NYSE:NVO) to make the Danish drugmaker's ...

Hims and Hers Health beat Wall Street estimates for third-quarter revenue on Monday, as the telehealth company added ...

Hims & Hers Health has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, ...

Less than six months after ending a short-lived partnership, US telehealth firm Hims & Hers (Nasdaq: HIMS) and Danish ...

Now, it’s worth noting Stock Advisor’s total average return is 1,036% — a market-crushing outperformance compared to 191 % ...

Discover why Hims & Hers Health (HIMS) remains a strong long-term buy after robust Q3 growth, new offerings, and expansion ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 4.9% in the afternoon session after news of increased ...

Hims & Hers Health, Inc. (NYSE:HIMS) saw its shares edge 1.5% higher on Monday after unveiling a fresh $250 million stock ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

After a tumultuous year, a popular virtual care platform is trying its hand in a competitive blood testing market.